Swedish research-based biopharma company BioArctic has entered an expanded research collaboration agreement with Uppsala University to offer financial support for a three-year research position.

This agreement is an expansion of the existing partnership between both the parties focused on developing a new type of PET ligand to enhance brain-imaging.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As part of the agreement, Department of Public Health and Caring Sciences, Molecular Geriatrics at the university will focus on developing technologies for antibody-based diagnostic imaging of the brain, termed as positron emission tomography (PET), in Alzheimer patients.

“This agreement is an expansion of the existing partnership between both the parties focussed on developing a new type of PET ligand to enhance brain-imaging.”

BioArctic CEO Gunilla Osswald said: “We look forward to continuing the research collaboration with Uppsala University regarding new PET ligands based on our antibodies.

“This initiative is of importance to the entire field of Alzheimer research. We hope that the results will contribute to improved diagnosis of Alzheimer patients in the future and thus to a more effective treatment.”

Alzheimer’s disease is currently diagnosed through clinical examinations, measurement of biochemical markers in spinal fluid and imaging of the brain.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The disease is caused by death of neurons in the brain causing a progressive deterioration of memory and cognitive skills, including intellectual ability, language, orientation, recognition and learning ability.

In addition, the research aims to offer an enhanced method in the diagnosis of Alzheimer’s disease as well as to evaluate the effect of pharmacological treatment in the long run.

Established in 2003, BioArctic offers disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact